ENDRA Life Sciences Inc. Quarterly Debt-to-equity in % from Q3 2017 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ENDRA Life Sciences Inc. quarterly Debt-to-equity history and growth rate from Q3 2017 to Q4 2024.
  • ENDRA Life Sciences Inc. Debt-to-equity for the quarter ending December 31, 2024 was 29.6 %, a 17.2% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 29.6 -6.14 -17.2% Dec 31, 2024
Q3 2024 22.8 -14.8 -39.4% Sep 30, 2024
Q2 2024 26.8 -3.29 -10.9% Jun 30, 2024
Q1 2024 33.4 +9.75 +41.2% Mar 31, 2024
Q4 2023 35.8 +15.6 +76.9% Dec 31, 2023
Q3 2023 37.5 +18.9 +102% Sep 30, 2023
Q2 2023 30.1 +12.6 +72.4% Jun 30, 2023
Q1 2023 23.7 +6.23 +35.7% Mar 31, 2023
Q4 2022 20.2 +6.93 +52.1% Dec 31, 2022
Q3 2022 18.6 +5.34 +40.3% Sep 30, 2022
Q2 2022 17.5 +1.49 +9.33% Jun 30, 2022
Q1 2022 17.4 -4.91 -22% Mar 31, 2022
Q4 2021 13.3 -39.4 -74.8% Dec 31, 2021
Q3 2021 13.3 -57.5 -81.2% Sep 30, 2021
Q2 2021 16 -70.9 -81.6% Jun 30, 2021
Q1 2021 22.3 -52.6 -70.2% Mar 31, 2021
Q4 2020 52.7 -5.2 -8.98% Dec 31, 2020
Q3 2020 70.8 +30.2 +74.3% Sep 30, 2020
Q2 2020 86.8 +43.7 +101% Jun 30, 2020
Q1 2020 74.9 +34.5 +85.2% Mar 31, 2020
Q4 2019 57.9 +13.5 +30.5% Dec 31, 2019
Q3 2019 40.6 -7 -14.7% Sep 30, 2019
Q2 2019 43.2 +25 +138% Jun 30, 2019
Q1 2019 40.4 +31 +327% Mar 31, 2019
Q4 2018 44.4 +27.2 +158% Dec 31, 2018
Q3 2018 47.6 +17.7 +59.4% Sep 30, 2018
Q2 2018 18.2 Jun 30, 2018
Q1 2018 9.47 Mar 31, 2018
Q4 2017 17.2 Dec 31, 2017
Q3 2017 29.9 Sep 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.